Pharma Focus Europe

Accurus Biosciences and ImmPACT Bio Establish Exclusive Global Licensing Agreement for a Promising CLDN18.2 Antibody with Potential Best-in-Class Attributes

Wednesday, January 17, 2024

Accurus Biosciences Inc. is delighted to announce the initiation of a global licensing agreement for its CLDN18.2 monoclonal antibody with ImmPACT Bio USA, Inc., a clinical-stage company dedicated to advancing next-generation chimeric antigen receptor (CAR) T-cell therapies.

Dr. Richard Zhang, CEO of Accurus, expressed enthusiasm, stating, "We are pleased that ImmPACT Bio has chosen to leverage our potentially superior CLDN18.2 antibody for the development of innovative CAR T therapies. We believe that ImmPACT's initiatives hold promise in delivering distinct and potent therapies for the benefit of cancer patients."

According to the terms of the agreement, Accurus Biosciences has exclusively granted worldwide rights to ImmPACT Bio for the development and commercialization of next-generation cell therapies utilizing a specified antibody from Accurus' CLDN18.2 antibody portfolio. Accurus will retain rights to develop and commercialize its CLDN18.2 antibody portfolio for all non-cell-based therapeutic applications. The financial details of the agreement have not been disclosed.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva